October 14th 2024
The Big Pharma commercialization playbook doesn’t work for emerging life sciences companies bootstrapping their way up. Exploring three strategies that could be the ingredients of a winning formula for startups.
Medical Affairs and Medical Science Liaison (MSL) Board Certification: A Comprehensive Review
June 10th 2020With the growth of the medical science liaison (MSL) role in mind, this article provides a comprehensive review of the board certification programs that are currently available to MSLs and other medical affairs professionals.
Pricing for Rare Disease and Curative Therapies: What’s Fair?
June 2nd 2020There has been a considerable amount of attention given to the rising costs of pharmaceutical and biotechnology therapies in the US. In early 2020, Charles River Associates conducted this research to determine what "fair" prices would be for these therapies.